BGA
TCRT icon

Belmont Global Advisors’s Alaunos Therapeutics TCRT Stock Holding History

Belmont Global Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$12.5M Buy
14,835
+2,715
+22% +$2.18M 11.85% 3
2016
Q2 		$9.98M Buy
12,120
+1,633
+16% +$1.78M 9.58% 4
2016
Q1 		$11.7M Buy
10,487
+1,000
+11% +$1.02M 11.87% 3
2015
Q4 		$11.8M Buy
9,487
+280
+3% +$463K 15.32% 1
2015
Q3 		$12.4M Sell
9,207
-641
-7% -$1.06M 21.12% 1
2015
Q2 		$17.7M Buy
9,848
+1,512
+18% +$2.35M 19.65% 1
2015
Q1 		$13.5M Sell
8,336
-2,504
-23% -$3.71M 13.69% 1
2014
Q4 		$8.24M Buy
10,840
+4,353
+67% +$2.31M 8.14% 1
2014
Q3 		$2.57M Sell
6,487
-5,416
-46% -$2.61M 2.01% 12
2014
Q2 		$7.2M Sell
11,903
-3,230
-21% -$1.8M 5.19% 2
2014
Q1 		$10.4M Sell
15,133
-1,967
-12% -$1.32M 8.74% 1
2013
Q4 		$11.1M Buy
+17,100
New +$10.2M 8.99% 1

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Belmont Global Advisors's TCRT Position: Q3 2016 in Review

Belmont Global Advisors increased its Alaunos Therapeutics (TCRT) stake by 22% in Q3 2016, buying an estimated $2.18M and bringing the position to 14,835 shares worth $12.5M. The position accounts for 11.85% of the portfolio, ranked #3.

Belmont Global Advisors first reported a position in TCRT in Q4 2013 and has held it in 12 quarters since. The position peaked at $17.7M in Q2 2015. 140 funds tracked by Wall St. Rank hold TCRT as of Q3 2016.

  • Belmont Global Advisors held 14,835 shares of Alaunos Therapeutics worth $12.5M as of Q3 2016.
  • Belmont Global Advisors bought 2,715 Alaunos Therapeutics shares in Q3 2016, an estimated $2.18M.
  • Alaunos Therapeutics made up 11.85% of Belmont Global Advisors's portfolio in Q3 2016, its #3 holding.
  • Belmont Global Advisors first reported a position in Alaunos Therapeutics in Q4 2013 and has held it in 12 quarters since.
  • Belmont Global Advisors's Alaunos Therapeutics position peaked at $17.7M in Q2 2015.
  • 140 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2016.

Based on Belmont Global Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.